Table 2 Summary baseline table of studies comparing AIAT vs. IIAT
Author Year | Country (Enrollment Period) | Study Design | Total Follow-up | Total N | Pathogen | Site of Infection | Mean Age (SD), yr | % Male | % IIAT | Timeliness of AIAT | Susceptibility reported |
|---|---|---|---|---|---|---|---|---|---|---|---|
Araujo 2016 [12] | Brazil (2009–2012; 2014–2014) | CC | ~ 55 days | 236 | MDR and Non-MDR PA | BSI: 100% | 52.7 (22.9) | 70.3 | 36 | < 24 h | Yes |
Dantas 2014 [15] | Brazil (2009–2011) | RC | ~ 55.4 days | 120 | Resistant and susceptible PA | BSI: 100% | 51.5 (3.2) | 63.3 | 28.3 | NR | NR |
Gonzales 2014 [13] | Colombia (2005–2008) | RC; CC | 30 days | 164 | PA | RS: 37.5%; Central venous catheter 28.6% | 56 (33.5) | 67.1 | 50 | < 48 h | Yes |
Pinheiro 2008 [17] | Brazil (2006–2007) | RC; CC | 30 days | 131 | PA | RS: 65.6%; BSI: 18.3%; UTI: 11.5% | 64.2 (18.4) | 50.4 | 37.3 | NR | Yes |
Tuon 2012 [16] | Brazil (2006–2009) | CC | 30 days | 77 | CRPA, CSPA | BSI: 100% | 48.0 | 72.7 | 52 | < 24 h | Yes |
Rossi 2017 [14] | Brazil (2009–2012) | CC | NR | 157 | PA 100% | Unknown: 62.42; RS: 17.19; BSI: 13.37 | 52.0 (24.5) | 66.9 | 31.2 | NR | Yes |